Carbamazepine (All indications)

Cleft lip with or without cleft palate

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9664
R34409		 Jentink (Carbamazepine), 2010 Cleft lip (with or without palate) 1st trimester case control unexposed (general population or NOS) Adjustment: Yes no data 1/-   -/- - -
ref
Total 1 studies NaN [NaN;NaN] 0 0
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Jentink (Carbamazepine), 2010Jentink, 2010 1 0.20[0.00; 1.30]--0%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies Jentink (Carbamazepine), 2010 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) Jentink (Carbamazepine), 2010 1 Tags Adjustment   - Yes  - Yes Jentink (Carbamazepine), 2010 1 All studiesAll studies Jentink (Carbamazepine), 2010 10.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.12[0.07; 17.92]1,637512 -NABlotière (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2019 1 unexposed, sick controlsunexposed, sick controls 0.59[0.09; 4.07]31,2380%NAVajda (Carbamazepine) (Controls unexposed, sick), 2013 Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 Artama (Carbamazepine), 2005 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.17[0.06; 24.43]2512 -NABlotière (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 10.510.01.0